Atlas Trials

This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.

Clinical trial NCT05858450 · COMPLETED

Trial details

NCT number
NCT05858450
Sponsor
Pfizer
Status
COMPLETED
Study type
OBSERVATIONAL
Influenza, HumanCOVID-19
Start date
2023-05-05
Primary completion
2023-05-12
Enrollment
3442996

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.